

Review Article



Endodontic biofilms: contemporary and future treatment options

Yeon-Jee Yoo ,¹ Hiran Perinpanayagam ,² Soram Oh ,³ A-Reum Kim ,⁴
Seung-Hyun Han ,⁴ Kee-Yeon Kum *

¹Department of Conservative Dentistry, Dental Research Institute, School of Dentistry, Seoul National University, Seoul, Korea

²Division of Restorative Dentistry, Schulich School of Medicine & Dentistry, University of Western Ontario, London, Canada

³Department of Conservative Dentistry, School of Dentistry, Kyung Hee University, Seoul, Korea

⁴Department of Oral Microbiology and Immunology, Dental Research Institute and BK21 Plus Program, School of Dentistry, Seoul National University, Seoul, Korea



Received: Nov 20, 2018

Accepted: Dec 26, 2018

Yoo YJ, Perinpanayagam H, Oh S, Kim AR, Han SH, Kum KY

*Correspondence to

Kee-Yeon Kum, DDS, MSD, PhD

Professor, Department of Conservative Dentistry, Dental Research Institute, Seoul Dental Hospital for Disabled, Seoul National University Dental Hospital, School of Dentistry, Seoul National University, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea.
E-mail: kum6139@snu.ac.kr

Copyright © 2019. The Korean Academy of Conservative Dentistry

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Funding

This work was supported by the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare (HI17C1377), Republic of Korea.

Conflict of Interest

No potential conflict of interest relevant to this article was reported.

ABSTRACT

Apical periodontitis is a biofilm-mediated infection. The biofilm protects bacteria from host defenses and increase their resistance to intracanal disinfecting protocols. Understanding the virulence of these endodontic microbiota within biofilm is essential for the development of novel therapeutic procedures for intracanal disinfection. Both the disruption of biofilms and the killing of their bacteria are necessary to effectively treat apical periodontitis. Accordingly, a review of endodontic biofilm types, antimicrobial resistance mechanisms, and current and future therapeutic procedures for endodontic biofilm is provided.

Keywords: Antimicrobial resistance; Endodontic biofilm; Intracanal disinfection; *Lactobacillus*; Lipoteichoic acid

ENDODONTIC BIOFILMS

Biofilms are sessile multicellular microbial communities where microbes are enmeshed in a self-made extracellular polymeric substance (EPS, usually a polysaccharide), and firmly attached to surfaces [1]. These surfaces include root canal walls that provide a niche for bacteria [2,3]. Despite intracanal disinfection and a drastically changed environment, bacteria can be detected in post-treatment samples.





Biofilm formation is dependent on a surface conditioning layer, the properties of which determine microbial attachment and composition, as microbes within a planktonic phase are delivered [3]. Bacterial attachment to the substrate is dependent on surface energy, temperature, pH, fluid flow rate, duration of contact, surface hydrophobicity, and nutrient availability [4]. Bacterial structures such as pili, flagella, EPS and polysaccharide-specific adhesins/ligands are important for adherence [5]. Proliferation and metabolism of attached microorganism creates structurally organized mixed microbial communities [3], and this monolayer then attracts secondary colonizers that form microcolonies and the final biofilm structure [6,7].

In endodontics, 4 types of biofilms, including intracanal, extraradicular, periapical, and biomaterial-centered biofilms were reported [4,8]. Nair reported that despite

Author Contributions

Conceptualization: Yoo YJ, Han SH, Kum KY; Data curation: Yoo YJ, Kim AR, Perinpanayagam H; Formal analysis: Yoo YJ, Kim AR; Funding acquisition: Kum KY; Investigation: Yoo YJ, Kim AR; Methodology: Perinpanayagam H, Kum KY; Project administration: Kum KY; Resources: Perinpanayagam H, Kim AR; Software: Kim AR, Oh S; Supervision: Han SH, Kum KY; Validation: Han SH, Kum KY; Visualization: Yoo YJ, Kim AR, Kum KY; Writing - original draft: Yoo YJ, Kim AR, Kum KY; Writing - review & editing: Yoo YJ, Perinpanayagam H, Han SH, Kum KY.

ORCID iDs

Yeon-Jee Yoo  <https://orcid.org/0000-0002-3931-7668>
Hiran Perinpanayagam  <https://orcid.org/0000-0001-6484-5932>
Soram Oh  <https://orcid.org/0000-0002-8843-2144>
A-Reum Kim  <https://orcid.org/0000-0003-4246-4316>
Seung-Hyun Han  <https://orcid.org/0000-0001-9418-9278>
Kee-Yeon Kum  <https://orcid.org/0000-0002-3032-3498>

instrumentation, irrigation, and obturation for single-visit treatment of mandibular first molars with primary apical periodontitis, microorganisms persisted within biofilms in untouched areas of canals and isthmuses [9], which is called as an intracanal biofilms.

Extradicular biofilms were reported in teeth with asymptomatic apical periodontitis, as well as those with chronic apical abscesses and sinus tract [4,8]. Ricucci *et al.* [10] discovered calculus-like deposits on root tips of teeth with secondary (post-treatment) apical periodontitis. Noiri *et al.* [11] found glycocalyx-like structures had almost completely covered gutta-percha cones recovered from beyond the apex, and bacteria on the external root surfaces in the extracted teeth in cases of 'refractory periapical pathosis'.

Certain strains can survive and infect periapical tissues as periapical biofilms [2]. *Propionibacterium propionicum* and various Actinomyces have been demonstrated in asymptomatic periapical lesions refractory to endodontic treatment [12]. Some Actinomyces have fimbriae for coaggregation, adherence to canal walls and dentinal debris forced through the apical foramen during treatment [13]. Bacteria may evade host defenses by building cohesive colonies including many branching and filamentous bacteria enmeshed in protein-polysaccharide matrix [13].

Bacteria can also adhere to artificial biomaterial surfaces and form biofilm structures [14] that cause biomaterial-centered infections. Gram-positive facultative anaerobes with serum colonize and form EPS on gutta-percha [14]. These biofilms on obturating materials can be both intra- and extra-radicular, when the material has extruded beyond the apex.

MECHANISMS OF ANTIMICROBIAL RESISTANCE

The polysaccharide matrix in biofilms retards diffusion of antibiotics and inactivating extracellular enzymes such as β -lactamase may become concentrated [15]. Microbial cells communicate by quorum sensing to encourage the growth of species beneficial to biofilm structure [1,16]. Subpopulations within a biofilm can alter gene expression to remain protected [17]. Cells remain interiorly where they are protected from medicaments that act only on the microorganisms in the biofilms periphery. Bacterial cells grow more slowly with less metabolism in biofilms than when planktonic, and thereby elude antimicrobial agents [15]. They halt growth with nutrient depletion or waste product accumulation, further protecting them from antibiotics [17]. The altered pH and oxygen level within biofilms may further impair antibiotics [18].

CURRENT AND FUTURE THERAPEUTIC STRATEGIES AGAINST ENDODONTIC BIOFILM

Irrigants for biofilm eradication

Microorganisms grown within biofilms are 1,000–1,500 times more resistant to antimicrobials than planktonic bacteria [6,19]. Sodium hypochlorite (NaOCl) has been widely used as an endodontic irrigant due to its potent antimicrobial action and necrotic tissue dissolving property. Regarding the recalcitrant bacteria, mostly *Enterococcus faecalis* (*E. faecalis*) biofilm, it was reported that treatment of *E. faecalis* lipoteichoic acid (LTA) with NaOCl resulted in the impairment of immunostimulating activity by the delipidation of

glycolipid moiety structure [20]. NaOCl could impair toll like receptor 2 activation of *E. faecalis* and induce inflammatory mediators, and damage the LTA structure, potentially through deacylation [20]. Furthermore, NaOCl is the most effective antimicrobial irrigant against multi-species biofilm [21]. Given that the dual-species biofilms or the aged biofilms were more resistant to NaOCl than monospecies biofilms or the young biofilms [22], many researches found that high concentration NaOCl was the only irrigant effective in disrupting multi-species biofilm and eradicating bacterial cells [23-26].

Chlorhexidine (CHX) digluconate is a broad spectrum antimicrobial disinfectant that has antimicrobial substantive activity [27-29], and thus has been widely used as an auxiliary canal irrigant or a canal soaking agent against *E. faecalis* biofilms [30,31]. A recent study demonstrated that CHX attenuates the activity of *E. faecalis* LTA [32]. Kim *et al.* [33] compared the antimicrobial activity of alexidine (1%) and CHX (2%) on *E. faecalis* by using dentin block model according to soaking time (5 and 10 minutes). And they found that there was no significant difference in the number of bacteria adhering after the first minute of exposure and the most effective irrigant at disrupting biofilms was NaOCl [25]. Despite these antimicrobial activities, CHX cannot be used as main root canal irrigant because it does not have tissue solvent activity [30].

In addition to smear layer removal, EDTA irrigation can be beneficial in disruption of biofilm. Ozdemir *et al.* [34] demonstrated that combination of EDTA and NaOCl significantly reduced the amount of intracanal biofilm in both young and old aged biofilms. Soares *et al.* [35] reported that the NaOCl-EDTA alternating irrigation was a promising regimen for elimination of intracanal *E. faecalis* biofilms.

Intracanal medicament for biofilm eradication

1. Calcium hydroxide

Calcium hydroxide (CH) is a widely used intracanal medicament that has broad antimicrobial activity, which is dependent on the release of aqueous hydroxyl ions to raise pH so that microbes cannot survive [36]. Elevated pH alters membrane integrity, and the hydroxyl ions are highly reactive with biomolecules [37].

Yet, intracanal CH was reported to be ineffective in preventing *E. faecalis* biofilm formation in root canals [19], while still being effective in eliminating their biofilm [38]. Brändle *et al.* [39] evaluated the effects of growth condition (planktonic, mono- and multi-species biofilms) on the susceptibility of *E. faecalis*, *Streptococcus sobrinus* (*S. sobrinus*), *Candida albicans* (*C. albicans*), *Actinomyces naeslundii* (*A. naeslundii*), and *Fusobacterium nucleatum* to alkaline stress. The findings showed that planktonic microorganisms were most susceptible; only *E. faecalis* and *C. albicans* survived in saturated solution for 10 minutes, and the latter also survived for 100 minutes [39]. Dentin adhesion was the major factor in improving the resistance of *E. faecalis* and *A. naeslundii* to CH, whereas the multispecies context in a biofilm was the major factor in promoting resistance of *S. sobrinus* to the disinfectant. In contrast, the *C. albicans* response to CH was not influenced by growth conditions [39].

In addition to the effect of hydroxyl ion, damage in the lipid moieties of bacterial virulence factors composed of glycolipids might be a unique detoxification mechanism of CH. *E. faecalis* is known to be resistant to CH, owing to their proton pump for internal pH maintenance and inhibitory dentin buffering effect. However, it was recently found that CH could attenuate

the abilities of not only *E. faecalis* but also its LTA to stimulate murine macrophages, and could reduce TNF- α or NO production [40]. As an underlying mechanism, Baik *et al.* [40] reported that CH could deacylate the LTA from *E. faecalis*, resulting in the impairment of LTA immunostimulating activity. CH can also inactivate lipopolysaccharide (LPS) in gram-negative bacteria, via hydrolysis of fatty acid in the lipid A moiety [41-44].

2. Chlorhexidine

Positively charged CHX molecules interact with negatively charged membrane phospholipids to enter and permeabilize microbial cells [45]. It was reported that CHX could alter cell walls and nucleoprotein coagulation, even in *C. albicans* [46,47]. In dentin block model, CHX showed superior antifungal activity compared to CH, up to 400 μ m depth dentinal tubules [46]. Additionally, CHX binds to hydroxyapatite and reduces microbial colonization on dentin surfaces, which provides substantive antimicrobial activity [27].

Subsequent analyses of biofilm spatial arrangements showed differences between the single- and dual-species biofilms in microstructural alterations in response to CHX exposure. Dual-species biofilms, but not single-species biofilms, had formed distinct clusters that were considered to account for the increased resistance to CHX [48].

3. Human beta defensins

Human beta defensins (HBDs) are cationic antimicrobial peptides that are critical host defense against microbes [49]. They bind to the negatively charged molecules on bacterial surface and disrupt bacterial membranes [50]. HBDs differ in amino acid sequences, structure, cysteine residues with disulfide bridges, charge, and affinity for bacterial membrane targets such as LPS in gram-negatives and LTA in gram-positives [51]. The antimicrobial effects of HBDs differ with bacterial strains due to variations in their LPS and LTA structure [52]. HBD-3 is strongly inhibitory, whereas HBD-1, -2, and -4 have weak antimicrobial effects on *E. faecalis* [53].

HBD-1, -2, -3, and -4 are produced in normal and inflamed dental pulp [54,55]. They may protect the pulp from inflammation induced by LTA of gram-positive bacteria and LPS of gram-negative bacteria [56]. Synthetic HBD-3 consisting of the C terminal 15 amino acids (HBD3-C15) was reported to be effective for disinfecting endodontic biofilm including *C. albicans* [46,57,58].

4. Triple antibiotic paste

Triple antibiotic paste (TAP), a mixture of metronidazole, ciprofloxacin, and minocycline, is widely used in regenerative endodontic procedure (REP). It is effective on infected dentin, intracanal biofilms, and the majority of endodontic pathogens [59-62]. But its toxicity to residual undifferentiated cells and periapical tissues limits its application in REP.

Laser-assisted eradication of biofilms

A low power laser directed at the access cavity combined with a photosensitizing agent was bactericidal on *S. intermedius* biofilms in root canals, but less effective than NaOCl (3%) irrigation [63]. Er:YAG laser was effective on apical root apex biofilms *in vitro* [64]. However, endodontic pathogens in biofilms were difficult to eradicate despite direct laser exposure *ex vivo* [65]. Er:YAG laser was effective against biofilms of *A. naeslundii*, *E. faecalis*, *Lactobacillus casei* (*L. casei*), *Propionibacterium acnes*, *F. nucleatum*, *Porphyromonas gingivalis*, or *Prevotella nigrescens*, *in vitro*, but not against biofilms of *L. casei* [66].

Effect of *Lactobacillus plantarum* LTA

Lactobacillus plantarum (*L. plantarum*) is a probiotic [67] that is known to have anti-inflammatory and anti-biofilm effect [68]. Bacterial cell wall components especially LTA inhibit *Streptococcus mutans* (*S. mutans*), *E. faecalis*, and *Staphylococcus aureus* (*S. aureus*) biofilm formation by controlling gene expression, quorum sensing, and inhibiting exopolysaccharides production [69-71]. Furthermore, *L. plantarum* LTA also disrupted preformed biofilm of *E. faecalis* and *S. aureus* [69,71]. Interestingly, *L. plantarum* LTA reduced not only mono-species biofilm, but also multi-species biofilm consisting of *A. naeslundii*, *E. faecalis*, *Lactobacillus salivarius*, and *S. mutans* [72], and it also cooperatively enhanced disruption of oral multispecies biofilm when combined with CH and CHX intracanal medicaments (unpublished data).

Effect of nanoparticles, photodynamic therapy, ozone, and enzymes

Nanoparticles synthesized from powders of silver, copper oxide, and zinc oxide, and other powders have broad antimicrobial applications [73]. These nanoparticles generate reactive oxygen species (ROS) that are cytotoxic for bacteria. Higher surface area and more charge density mean greater potential for bacterial interactions. Numerous positively charged nanoparticles accumulate on negatively charged bacterial cell membranes, which increase permeability to destroy cells [74-76]. Additionally, cationic nanoparticles adhere to negatively charged dentin surface to prevent biofilm formation [77].

In photodynamic therapy (PDT), a photosensitizer is preferentially localized in tissue and subsequently activated by appropriate wavelength light to generate reactive oxygen that kill bacteria [78]. There have been numerous *in vitro* studies on PDT in root canal disinfection [79-83]. However, penetration of the activating light and the photosensitizer may be limited within root canal structures. When microorganisms were sensitized with methylene blue (25 µg/mL, 5 minutes), all bacterial species except *E. faecalis* (53% killing) were destroyed. When this was followed by the addition of red light CH (222 J/cm²) with an optical fiber, almost all (97%) *E. faecalis* biofilm bacteria in root canals were eliminated [83].

Ozone gas (HealOzone, KaVo, Biberach, Germany) has yielded inconsistent result in destroying endodontic pathogens. These inconsistencies may have been due to variation in concentration and duration of application [84-86]. There is conflicting evidence on its antimicrobial efficacy and reduced effects on sessile versus planktonic bacteria [87].

Natural plant extracts such as polyphenols, *Morinda citrifolia*, and turmeric, as well as enzymes, such as dispersin B and proteinase K, have been proposed for treating biofilm medicated infections. But studies are needed to demonstrate their efficacy.

CONCLUSIONS

Endodontic infection is caused by the surface-associated growth of microorganisms. Applying the biofilm concept to endodontic microbiology helps to understand the pathogenic potential of the root canal microbiota and to form the basis of new approaches in root canal disinfection. Recent developments in biocompatible intracanal medicaments including synthetic HBDs and *L. plantarum* LTA could open up new avenues as an ideal therapeutic agent to eradicate endodontic biofilm.

REFERENCES

1. Siqueira JF Jr, Rôças IN. Clinical implications and microbiology of bacterial persistence after treatment procedures. *J Endod* 2008;34:1291-1301.e3.
[PUBMED](#) | [CROSSREF](#)
2. Chavez de Paz LE. Redefining the persistent infection in root canals: possible role of biofilm communities. *J Endod* 2007;33:652-662.
[PUBMED](#) | [CROSSREF](#)
3. Svensater G, Bergenholtz G. Biofilms in endodontic infections. *Endod Topics* 2004;9:27-36.
[CROSSREF](#)
4. Ingle JI, Bakland LK, Baumgartner JC. *Ingle's Endodontics*. 6th ed. Lewiston, PA: PMPH-USA; 2008. p268-285.
5. Grenier D, Mayrand D. Nutritional relationships between oral bacteria. *Infect Immun* 1986;53:616-620.
[PUBMED](#)
6. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. *Science* 1999;284:1318-1322.
[PUBMED](#) | [CROSSREF](#)
7. Cowan MM, Taylor KG, Doyle RJ. Energetics of the initial phase of adhesion of *Streptococcus sanguis* to hydroxylapatite. *J Bacteriol* 1987;169:2995-3000.
[PUBMED](#) | [CROSSREF](#)
8. Mohammadi Z, Palazzi F, Giardino L, Shalavi S. Microbial biofilms in endodontic infections: an update review. *Biomed J* 2013;36:59-70.
[PUBMED](#) | [CROSSREF](#)
9. Nair PN, Henry S, Cano V, Vera J. Microbial status of apical root canal system of human mandibular first molars with primary apical periodontitis after "one-visit" endodontic treatment. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2005;99:231-252.
[PUBMED](#) | [CROSSREF](#)
10. Ricucci D, Martorano M, Bate AL, Pascon EA. Calculus-like deposit on the apical external root surface of teeth with post-treatment apical periodontitis: report of two cases. *Int Endod J* 2005;38:262-271.
[PUBMED](#) | [CROSSREF](#)
11. Noiri Y, Ehara A, Kawahara T, Takemura N, Ebisu S. Participation of bacterial biofilms in refractory and chronic periapical periodontitis. *J Endod* 2002;28:679-683.
[PUBMED](#) | [CROSSREF](#)
12. Siqueira JF Jr. Periapical actinomycosis and infection with *Propionibacterium propionicum*. *Endod Topics* 2003;6:78-95.
[CROSSREF](#)
13. Figdor D, Sjögren U, Sörlin S, Sundqvist G, Nair PN. Pathogenicity of *Actinomyces israelii* and *Arachnia propionica*: experimental infection in guinea pigs and phagocytosis and intracellular killing by human polymorphonuclear leukocytes *in vitro*. *Oral Microbiol Immunol* 1992;7:129-136.
[PUBMED](#) | [CROSSREF](#)
14. Wilson M. Susceptibility of oral bacterial biofilms to antimicrobial agents. *J Med Microbiol* 1996;44:79-87.
[PUBMED](#) | [CROSSREF](#)
15. Dunavant TR, Regan JD, Glickman GN, Solomon ES, Honeyman AL. Comparative evaluation of endodontic irrigants against *Enterococcus faecalis* biofilms. *J Endod* 2006;32:527-531.
[PUBMED](#) | [CROSSREF](#)
16. Larsen T. Susceptibility of *Porphyromonas gingivalis* in biofilms to amoxicillin, doxycycline and metronidazole. *Oral Microbiol Immunol* 2002;17:267-271.
[PUBMED](#) | [CROSSREF](#)
17. Portenier I, Waltimo TM, Haapasalo M. *Enterococcus faecalis*: the root canal survivor and 'star' in post-treatment disease. *Endod Topics* 2003;6:135-159.
[CROSSREF](#)
18. Athanassiadis B, Abbott PV, Walsh LJ. The use of calcium hydroxide, antibiotics and biocides as antimicrobial medicaments in endodontics. *Aust Dent J* 2007;52:S64-S82.
[PUBMED](#) | [CROSSREF](#)
19. Distel JW, Hatton JF, Gillespie MJ. Biofilm formation in medicated root canals. *J Endod* 2002;28:689-693.
[PUBMED](#) | [CROSSREF](#)
20. Hong SW, Baik JE, Kang SS, Kum KY, Yun CH, Han SH. Sodium hypochlorite inactivates lipoteichoic acid of *Enterococcus faecalis* by deacylation. *J Endod* 2016;42:1503-1508.
[PUBMED](#) | [CROSSREF](#)

21. Spratt DA, Pratten J, Wilson M, Gulabivala K. An *in vitro* evaluation of the antimicrobial efficacy of irrigants on biofilms of root canal isolates. *Int Endod J* 2001;34:300-307.
[PUBMED](#) | [CROSSREF](#)
22. Ozok AR, Wu MK, Luppens SB, Wesselink PR. Comparison of growth and susceptibility to sodium hypochlorite of mono- and dual-species biofilms of *Fusobacterium nucleatum* and *Peptostreptococcus (micromonas) micros*. *J Endod* 2007;33:819-822.
[PUBMED](#) | [CROSSREF](#)
23. Clegg MS, Vertucci FJ, Walker C, Belanger M, Britto LR. The effect of exposure to irrigant solutions on apical dentin biofilms *in vitro*. *J Endod* 2006;32:434-437.
[PUBMED](#) | [CROSSREF](#)
24. Giardino L, Ambu E, Savoldi E, Rimondini R, Cassanelli C, Debbia EA. Comparative evaluation of antimicrobial efficacy of sodium hypochlorite, MTAD, and Tetraclean against *Enterococcus faecalis* biofilm. *J Endod* 2007;33:852-855.
[PUBMED](#) | [CROSSREF](#)
25. Bryce G, O'Donnell D, Ready D, Ng YL, Pratten J, Gulabivala K. Contemporary root canal irrigants are able to disrupt and eradicate single- and dual-species biofilms. *J Endod* 2009;35:1243-1248.
[PUBMED](#) | [CROSSREF](#)
26. Baca P, Junco P, Arias-Moliz MT, González-Rodríguez MP, Ferrer-Luque CM. Residual and antimicrobial activity of final irrigation protocols on *Enterococcus faecalis* biofilm in dentin. *J Endod* 2011;37:363-366.
[PUBMED](#) | [CROSSREF](#)
27. Parsons GJ, Patterson SS, Miller CH, Katz S, Kafrawy AH, Newton CW. Uptake and release of chlorhexidine by bovine pulp and dentin specimens and their subsequent acquisition of antibacterial properties. *Oral Surg Oral Med Oral Pathol* 1980;49:455-459.
[PUBMED](#) | [CROSSREF](#)
28. Basrani B, Santos JM, Tjäderhane L, Grad H, Gorduysus O, Huang J, Lawrence HP, Friedman S. Substantive antimicrobial activity in chlorhexidine-treated human root dentin. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2002;94:240-245.
[PUBMED](#) | [CROSSREF](#)
29. Baca P, Junco P, Arias-Moliz MT, Castillo F, Rodríguez-Archilla A, Ferrer-Luque CM. Antimicrobial substantivity over time of chlorhexidine and cetrimide. *J Endod* 2012;38:927-930.
[PUBMED](#) | [CROSSREF](#)
30. Mohammadi Z, Abbott PV. The properties and applications of chlorhexidine in endodontics. *Int Endod J* 2009;42:288-302.
[PUBMED](#) | [CROSSREF](#)
31. Gomes BP, Ferraz CC, Vianna ME, Berber VB, Teixeira FB, Souza-Filho FJ. *In vitro* antimicrobial activity of several concentrations of sodium hypochlorite and chlorhexidine gluconate in the elimination of *Enterococcus faecalis*. *Int Endod J* 2001;34:424-428.
[PUBMED](#) | [CROSSREF](#)
32. Lee JK, Baik JE, Yun CH, Lee K, Han SH, Lee W, Bae KS, Baek SH, Lee Y, Son WJ, Kum KY. Chlorhexidine gluconate attenuates the ability of lipoteichoic acid from *Enterococcus faecalis* to stimulate toll-like receptor 2. *J Endod* 2009;35:212-215.
[PUBMED](#) | [CROSSREF](#)
33. Kim HS, Woo Chang S, Baek SH, Han SH, Lee Y, Zhu Q, Kum KY. Antimicrobial effect of alexidine and chlorhexidine against *Enterococcus faecalis* infection. *Int J Oral Sci* 2013;5:26-31.
[PUBMED](#) | [CROSSREF](#)
34. Ozdemir HO, Buzoglu HD, Calt S, Stabholz A, Steinberg D. Effect of ethylenediaminetetraacetic acid and sodium hypochlorite irrigation on *Enterococcus faecalis* biofilm colonization in young and old human root canal dentin: *in vitro* study. *J Endod* 2010;36:842-846.
[PUBMED](#) | [CROSSREF](#)
35. Soares JA, Roque de Carvalho MA, Cunha Santos SM, Mendonça RM, Ribeiro-Sobrinho AP, Brito-Júnior M, Magalhães PP, Santos MH, de Macêdo Farias L. Effectiveness of chemomechanical preparation with alternating use of sodium hypochlorite and EDTA in eliminating intracanal *Enterococcus faecalis* biofilm. *J Endod* 2010;36:894-898.
[PUBMED](#) | [CROSSREF](#)
36. Siqueira JF Jr. Strategies to treat infected root canals. *J Calif Dent Assoc* 2001;29:825-837.
[PUBMED](#)
37. Siqueira JF Jr, Lopes HP. Mechanisms of antimicrobial activity of calcium hydroxide: a critical review. *Int Endod J* 1999;32:361-369.
[PUBMED](#) | [CROSSREF](#)

38. Chai WL, Hamimah H, Cheng SC, Sallam AA, Abdullah M. Susceptibility of *Enterococcus faecalis* biofilm to antibiotics and calcium hydroxide. *J Oral Sci* 2007;49:161-166.
[PUBMED](#) | [CROSSREF](#)
39. Brändle N, Zehnder M, Weiger R, Waltimo T. Impact of growth conditions on susceptibility of five microbial species to alkaline stress. *J Endod* 2008;34:579-582.
[PUBMED](#) | [CROSSREF](#)
40. Baik JE, Jang KS, Kang SS, Yun CH, Lee K, Kim BG, Kum KY, Han SH. Calcium hydroxide inactivates lipoteichoic acid from *Enterococcus faecalis* through deacylation of the lipid moiety. *J Endod* 2011;37:191-196.
[PUBMED](#) | [CROSSREF](#)
41. Safavi KE, Nichols FC. Effect of calcium hydroxide on bacterial lipopolysaccharide. *J Endod* 1993;19:76-78.
[PUBMED](#) | [CROSSREF](#)
42. Barthel CR, Levin LG, Reisner HM, Trope M. TNF-alpha release in monocytes after exposure to calcium hydroxide treated *Escherichia coli* LPS. *Int Endod J* 1997;30:155-159.
[PUBMED](#) | [CROSSREF](#)
43. Jiang J, Zuo J, Chen SH, Holliday LS. Calcium hydroxide reduces lipopolysaccharide-stimulated osteoclast formation. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2003;95:348-354.
[PUBMED](#) | [CROSSREF](#)
44. Buck RA, Cai J, Eleazer PD, Staat RH, Hurst HE. Detoxification of endotoxin by endodontic irrigants and calcium hydroxide. *J Endod* 2001;27:325-327.
[PUBMED](#) | [CROSSREF](#)
45. Bobichon H, Bouchet P. Action of chlorhexidine on budding *Candida albicans*: scanning and transmission electron microscopic study. *Mycopathologia* 1987;100:27-35.
[PUBMED](#) | [CROSSREF](#)
46. Yoo YJ, Kwon I, Oh SR, Perinpanayagam H, Lim SM, Ahn KB, Lee Y, Han SH, Chang SW, Baek SH, Zhu Q, Kum KY. Antifungal effects of synthetic human beta-defensin-3-C15 peptide on *Candida albicans*-infected root dentin. *J Endod* 2017;43:1857-1861.
[PUBMED](#) | [CROSSREF](#)
47. Krithikadatta J, Indira R, Dorothykalyani AL. Disinfection of dentinal tubules with 2% chlorhexidine, 2% metronidazole, bioactive glass when compared with calcium hydroxide as intracanal medicaments. *J Endod* 2007;33:1473-1476.
[PUBMED](#) | [CROSSREF](#)
48. Kara D, Luppens SB, van Marle J, Ozok R, ten Cate JM. Microstructural differences between single-species and dual-species biofilms of *Streptococcus mutans* and *Veillonella parvula*, before and after exposure to chlorhexidine. *FEMS Microbiol Lett* 2007;271:90-97.
[PUBMED](#) | [CROSSREF](#)
49. Zasloff M. Antimicrobial peptides of multicellular organisms. *Nature* 2002;415:389-395.
[PUBMED](#) | [CROSSREF](#)
50. Selsted ME, Ouellette AJ. Mammalian defensins in the antimicrobial immune response. *Nat Immunol* 2005;6:551-557.
[PUBMED](#) | [CROSSREF](#)
51. Schneider JJ, Unholzer A, Schaller M, Schäfer-Korting M, Korting HC. Human defensins. *J Mol Med (Berl)* 2005;83:587-595.
[PUBMED](#) | [CROSSREF](#)
52. Lee SH, Jun HK, Lee HR, Chung CP, Choi BK. Antibacterial and lipopolysaccharide (LPS)-neutralising activity of human cationic antimicrobial peptides against periodontopathogens. *Int J Antimicrob Agents* 2010;35:138-145.
[PUBMED](#) | [CROSSREF](#)
53. Lee SH, Baek DH. Antibacterial and neutralizing effect of human β -defensins on *Enterococcus faecalis* and *Enterococcus faecalis* lipoteichoic acid. *J Endod* 2012;38:351-356.
[PUBMED](#) | [CROSSREF](#)
54. Yamaguchi Y, Nagase T, Makita R, Fukuhara S, Tomita T, Tominaga T, Kurihara H, Ouchi Y. Identification of multiple novel epididymis-specific beta-defensin isoforms in humans and mice. *J Immunol* 2002;169:2516-2523.
[PUBMED](#) | [CROSSREF](#)
55. Paris S, Wolgin M, Kielbassa AM, Pries A, Zakrzewicz A. Gene expression of human beta-defensins in healthy and inflamed human dental pulps. *J Endod* 2009;35:520-523.
[PUBMED](#) | [CROSSREF](#)
56. Giacometti A, Cirioni O, Ghiselli R, Mocchegiani F, Del Prete MS, Viticchi C, Kamysz W, Łempicka E, Saba V, Scalise G. Potential therapeutic role of cationic peptides in three experimental models of septic shock. *Antimicrob Agents Chemother* 2002;46:2132-2136.
[PUBMED](#) | [CROSSREF](#)

57. Ahn KB, Kim AR, Kum KY, Yun CH, Han SH. The synthetic human beta-defensin-3 C15 peptide exhibits antimicrobial activity against *Streptococcus mutans*, both alone and in combination with dental disinfectants. *J Microbiol* 2017;55:830-836.
[PUBMED](#) | [CROSSREF](#)
58. Lim SM, Ahn KB, Kim C, Kum JW, Perinpanayagam H, Gu Y, Yoo YJ, Chang SW, Han SH, Shon WJ, Lee W, Baek SH, Zhu Q, Kum KY. Antifungal effects of synthetic human β -defensin 3-C15 peptide. *Restor Dent Endod* 2016;41:91-97.
[PUBMED](#) | [CROSSREF](#)
59. Windley W 3rd, Teixeira F, Levin L, Sigurdsson A, Trope M. Disinfection of immature teeth with a triple antibiotic paste. *J Endod* 2005;31:439-443.
[PUBMED](#) | [CROSSREF](#)
60. Hoshino E, Kurihara-Ando N, Sato I, Uematsu H, Sato M, Kota K, Iwaku M. *In-vitro* antibacterial susceptibility of bacteria taken from infected root dentine to a mixture of ciprofloxacin, metronidazole and minocycline. *Int Endod J* 1996;29:125-130.
[PUBMED](#) | [CROSSREF](#)
61. Sato I, Ando-Kurihara N, Kota K, Iwaku M, Hoshino E. Sterilization of infected root-canal dentine by topical application of a mixture of ciprofloxacin, metronidazole and minocycline *in situ*. *Int Endod J* 1996;29:118-124.
[PUBMED](#) | [CROSSREF](#)
62. Ordinola-Zapata R, Bramante CM, Minotti PG, Cavenago BC, Garcia RB, Bernardineli N, Jaramillo DE, Hungaro Duarte MA. Antimicrobial activity of triantibiotic paste, 2% chlorhexidine gel, and calcium hydroxide on an intraoral-infected dentin biofilm model. *J Endod* 2013;39:115-118.
[PUBMED](#) | [CROSSREF](#)
63. Seal GJ, Ng YL, Spratt D, Bhatti M, Gulabivala K. An *in vitro* comparison of the bactericidal efficacy of lethal photosensitization or sodium hypochlorite irrigation on *Streptococcus intermedius* biofilms in root canals. *Int Endod J* 2002;35:268-274.
[PUBMED](#) | [CROSSREF](#)
64. Araki AT, Ibraki Y, Kawakami T, Lage-Marques JL. Er:Yag laser irradiation of the microbiological apical biofilm. *Braz Dent J* 2006;17:296-299.
[PUBMED](#) | [CROSSREF](#)
65. Bergmans L, Moisiadis P, Teughels W, Van Meerbeek B, Quirynen M, Lambrechts P. Bactericidal effect of Nd:YAG laser irradiation on some endodontic pathogens *ex vivo*. *Int Endod J* 2006;39:547-557.
[PUBMED](#) | [CROSSREF](#)
66. Noiri Y, Katsumoto T, Azakami H, Ebisu S. Effects of Er:YAG laser irradiation on biofilm-forming bacteria associated with endodontic pathogens *in vitro*. *J Endod* 2008;34:826-829.
[PUBMED](#) | [CROSSREF](#)
67. Isolauri E. Probiotics in human disease. *Am J Clin Nutr* 2001;73:1142S-1146S.
[PUBMED](#) | [CROSSREF](#)
68. Söderling EM, Marttinen AM, Haukioja AL. Probiotic lactobacilli interfere with *Streptococcus mutans* biofilm formation *in vitro*. *Curr Microbiol* 2011;62:618-622.
[PUBMED](#) | [CROSSREF](#)
69. Ahn KB, Baik JE, Yun CH, Han SH. Lipoteichoic acid inhibits *Staphylococcus aureus* biofilm formation. *Front Microbiol* 2018;9:327.
[PUBMED](#) | [CROSSREF](#)
70. Ahn KB, Baik JE, Park OJ, Yun CH, Han SH. *Lactobacillus plantarum* lipoteichoic acid inhibits biofilm formation of *Streptococcus mutans*. *PLoS One* 2018;13:e0192694.
[PUBMED](#) | [CROSSREF](#)
71. Jung S, Park OJ, Kim AR, Ahn KB, Lee D, Kum KY, Yun CH, Han SH. Lipoteichoic acids of lactobacilli inhibit *Enterococcus faecalis* biofilm formation and disrupt the preformed biofilm. *J Microbiol* 2019 Jan 22. doi: 10.1007/s12275-019-8538-4. [Epub ahead of print]
[PUBMED](#) | [CROSSREF](#)
72. Kim AR, Ahn KB, Yoon SH, Yoo YJ, Perinpanayagam H, Kum KY, Han SH. *Lactobacillus plantarum* lipoteichoic acid inhibits oral multispecies biofilm. *J Endod*. 2019 Jan. doi: 10.1016/j.joen.2018.12.007. [accepted].
73. Kim JS, Kuk E, Yu KN, Kim JH, Park SJ, Lee HJ, Kim SH, Park YK, Park YH, Hwang CY, Kim YK, Lee YS, Jeong DH, Cho MH. Antimicrobial effects of silver nanoparticles. *Nanomedicine (Lond)* 2007;3:95-101.
[PUBMED](#) | [CROSSREF](#)
74. Sawai J. Quantitative evaluation of antibacterial activities of metallic oxide powders (ZnO, MgO and CaO) by conductimetric assay. *J Microbiol Methods* 2003;54:177-182.
[PUBMED](#) | [CROSSREF](#)

75. Beard SJ, Hughes MN, Poole RK. Inhibition of the cytochrome bd-terminated NADH oxidase system in *Escherichia coli* K-12 by divalent metal cations. *FEMS Microbiol Lett* 1995;131:205-210.
[PUBMED](#) | [CROSSREF](#)
76. Feng QL, Wu J, Chen GQ, Cui FZ, Kim TN, Kim JO. A mechanistic study of the antibacterial effect of silver ions on *Escherichia coli* and *Staphylococcus aureus*. *J Biomed Mater Res* 2000;52:662-668.
[PUBMED](#) | [CROSSREF](#)
77. Kishen A, Sum CP, Mathew S, Lim CT. Influence of irrigation regimens on the adherence of *Enterococcus faecalis* to root canal dentin. *J Endod* 2008;34:850-854.
[PUBMED](#) | [CROSSREF](#)
78. Dai T, Huang YY, Hamblin MR. Photodynamic therapy for localized infections--state of the art. *Photodiagnosis Photodyn Ther* 2009;6:170-188.
[PUBMED](#) | [CROSSREF](#)
79. Meire MA, De Prijk K, Coenye T, Nelis HJ, De Moor RJ. Effectiveness of different laser systems to kill *Enterococcus faecalis* in aqueous suspension and in an infected tooth model. *Int Endod J* 2009;42:351-359.
[PUBMED](#) | [CROSSREF](#)
80. George S, Kishen A. Photophysical, photochemical, and photobiological characterization of methylene blue formulations for light-activated root canal disinfection. *J Biomed Opt* 2007;12:034029.
[PUBMED](#) | [CROSSREF](#)
81. George S, Kishen A. Influence of photosensitizer solvent on the mechanisms of photoactivated killing of *Enterococcus faecalis*. *Photochem Photobiol* 2008;84:734-740.
[PUBMED](#) | [CROSSREF](#)
82. George S, Kishen A. Augmenting the antibiofilm efficacy of advanced noninvasive light activated disinfection with emulsified oxidizer and oxygen carrier. *J Endod* 2008;34:1119-1123.
[PUBMED](#) | [CROSSREF](#)
83. Soukos NS, Chen PS, Morris JT, Ruggiero K, Abernethy AD, Som S, Foschi F, Doucette S, Bammann LL, Fontana CR, Doukas AG, Stashenko PP. Photodynamic therapy for endodontic disinfection. *J Endod* 2006;32:979-984.
[PUBMED](#) | [CROSSREF](#)
84. Nagayoshi M, Kitamura C, Fukuizumi T, Nishihara T, Terashita M. Antimicrobial effect of ozonated water on bacteria invading dentinal tubules. *J Endod* 2004;30:778-781.
[PUBMED](#) | [CROSSREF](#)
85. Arita M, Nagayoshi M, Fukuizumi T, Okinaga T, Masumi S, Morikawa M, Kakinoki Y, Nishihara T. Microbicidal efficacy of ozonated water against *Candida albicans* adhering to acrylic denture plates. *Oral Microbiol Immunol* 2005;20:206-210.
[PUBMED](#) | [CROSSREF](#)
86. Hems RS, Gulabivala K, Ng YL, Ready D, Spratt DA. An *in vitro* evaluation of the ability of ozone to kill a strain of *Enterococcus faecalis*. *Int Endod J* 2005;38:22-29.
[PUBMED](#) | [CROSSREF](#)
87. Azarpazhooh A, Limeback H. The application of ozone in dentistry: a systematic review of literature. *J Dent* 2008;36:104-116.
[PUBMED](#) | [CROSSREF](#)